Latest news with #ShortBowelSyndrome
Yahoo
02-08-2025
- Business
- Yahoo
OPKO Health (OPK) to Present Short Bowel Syndrome Treatment in Prague
OPKO Health, Inc. (NASDAQ:OPK) is one of the penny stocks that will skyrocket. On July 8, the company confirmed that its oral GLP-2 tablet tailored for short bowel syndrome will be presented at the 47th European Society for Clinical Nutrition & Metabolism Congress in Prague. Stokkete/ The presentation is to be made on September 13, as part of an abstract titled 'First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome.' OPKO Health is developing an oral GLP-2 tablet in combination with Entera while leveraging its long-acting GLP-2 agonist. 'Given the heterogeneity of patients with SBS and challenging compliance rates attributed to injectable GLP-2 therapy, we believe a daily tablet format may enable more personalized care of this peptide and individualize titration,' said Miranda Toledano, Entera's Chief Executive Officer. The oral GLP-2 tablet targets the short bowel syndrome, a rare malabsorptive condition caused by significant loss of functional or physical bowel mass. The condition is characterized by the body's failure to absorb nutrients and fluids, therefore putting patients at risk of malnutrition and unintended weight loss. OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company that develops and commercializes pharmaceutical and diagnostic products. It creates solutions for serious diseases, including cancer and infectious diseases, leveraging pharmaceutical and diagnostic expertise. While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-07-2025
- Business
- Yahoo
OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
OPKO Health, Inc. (NASDAQ:OPK) is one of the . On July 8, OPKO Health, Inc. (NASDAQ:OPK) in collaboration with Entera Bio Ltd. (NASDAQ: ENTX) announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress. This new therapy is a first in class and combines OPKO Health, Inc.'s (NASDAQ:OPK) long-acting GLP-2 agonist with Entera's N-Tab technology. The display will be in the Forum Hall Foyer 3, focusing on liver and gastrointestinal tract topics. The therapy treats short bowel syndrome, which is a condition where patients struggle to absorb nutrients due to a damaged or shortened intestine. Currently, the only approved treatment is GATTEX, which requires patients to inject themselves once a day. The oral GLP-2 tablet could change this. It aims to provide the same benefits without painful injections. This format may improve patient compliance and comfort. A doctor in scrubs discussing a patient's test results with a small group of concerned family members. OPKO Health, Inc. (NASDAQ:OPK) is an international biopharmaceutical company that develops and sells medicines, including human growth hormone and treatments for kidney disease. While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
08-07-2025
- Business
- Yahoo
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) ('OPKO') and Entera Bio Ltd. (NASDAQ: ENTX) ('Entera') today announced that their abstract 'First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome' has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism ('ESPEN') Congress, taking place September 13–16, 2025, in Prague, Czech Republic. Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel SyndromePoster Viewing Date & Time: September 13, 2025, 3:30 - 4:00 p.m. local time & Welcome ReceptionPoster Topic: Poster Session 1 - Liver and gastrointestinal tractLocation of Display: Forum Hall Foyer 3 The oral GLP-2 tablet program combines a proprietary long acting GLP-2 agonist developed by OPKO with Entera's proprietary N-Tab™ technology for patients suffering from short bowel syndrome and additional disorders involving gastrointestinal mucosal inflammation and nutrient malabsorption. Currently, the only approved GLP-2 agonist, which is marketed under the brand GATTEX® (teduglutide), requires daily subcutaneous injections. 'Given the heterogeneity of patients with SBS and challenging compliance rates attributed to injectable GLP-2 therapy, we believe a daily tablet format may enable more personalized care of this peptide and individualize titration,' said Miranda Toledano, Entera Chief Executive Officer. About Short Bowel Syndrome Short bowel syndrome (SBS) is a rare and potentially life-threatening malabsorptive condition caused by a significant loss of functional bowel mass (secondary to congenital defects or disease-associated loss of absorption) or physical bowel mass (secondary to extensive intestinal resection). Approximately 30,000 patients across the US and EU are living with SBS, and current annual sales of GATTEX® (teduglutide), the only approved therapy for SBS, total roughly $800 million. SBS patients have a reduced ability to absorb nutrients and fluids and are at risk of malnutrition, unintended weight loss and additional symptoms due to the loss of essential vitamins and minerals1. SBS is the most common cause of chronic intestinal failure, accounting for approximately 75% of chronic intestinal failure cases in adults and 50% of such events in children.2 About Entera Bio Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab™) and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company's most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n=161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA's qualification of a quantitative BMD endpoint. The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit or follow us on LinkedIn, Twitter, Facebook, Instagram. About OPKO Health OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and its novel and proprietary technologies. For more information, visit Cautionary Statement Regarding Forward Looking Statements Various statements in this presentation are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Words such as, but not limited to, 'anticipate,' 'believe,' 'can,' 'could,' 'expect,' 'estimate,' 'design,' 'goal,' 'intend,' 'may,' 'might,' 'objective,' 'plan,' 'predict,' 'project,' 'target,' 'likely,' 'should,' 'will,' and 'would,' or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera's and OPKO's forward-looking statements include, among others: results of our clinical trials; the anticipated benefits of an oral tablet for the treatment of SBS; and other factors that are described in the 'Cautionary Statements Regarding Forward-Looking Statements,' 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of each of Entera's and OPKO's most recent Annual Reports on Form 10-K filed with the SEC, as well as the companies' respective subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera and OPKO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera or OPKO, as applicable. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera and OPKO caution investors not to rely on the forward-looking statements made in this press release. The information in this press release is provided only as of the date of this press release, and neither Entera nor OPKO undertakes any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law. Contacts: Entera BioMiranda ToledanoChief Executive Officermiranda@ OPKO HealthAlliance Advisors IRYvonne Briggs, 310-691-7100ybriggs@ or Bruce Voss, 310-691-7100 bvoss@ 1 2 Zhu C, Li Y. An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults. J Int Med Res. 2022 Mar;50(3):3000605221086145. doi: 10.1177/03000605221086145. PMID: 35343263; PMCID: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
29-05-2025
- Health
- Time of India
What is short bowel syndrome? How serious is it?
When 4-year-old S.G.V. appeared at a recent press conference in Los Angeles, she seemed like any other preschooler—quietly coloring and playing cards. But the backpack strapped to her shoulders told a different story. Inside it was the equipment delivering life-sustaining nutrition directly into her bloodstream, a treatment known as Total Parenteral Nutrition (TPN). S.G.V. lives with short bowel syndrome (SBS), a rare but serious condition that makes her unable to absorb nutrients from food. Without the nightly intravenous nutrition she receives in the U.S., doctors say she would not survive more than a few days. Her case recently drew national attention because of a change to her family's immigration status, which threatens to interrupt the care that keeps her alive. But beyond the legal battle is a far more urgent medical issue: What exactly is short bowel syndrome, and why is it so dangerous? What is Short Bowel Syndrome? According to the Mayo Clinic, short bowel syndrome is a condition in which the body cannot absorb enough nutrients from the food you eat because part of the small intestine is missing or damaged. The small intestine is where most nutrients are absorbed during digestion. When a large portion of it is removed or doesn't function properly, the body can't get enough protein, fat, carbohydrates, vitamins, or minerals to survive. SBS can happen in two ways: A person is born with part of the intestine missing or damaged. A person has to have large sections of the small intestine surgically removed due to conditions like Crohn's disease, cancer, trauma, or blood clots in the intestinal arteries. How does it affect the body? The Cleveland Clinic explains that while the body has some ability to adapt to small intestinal changes, losing too much—especially the jejunum or ileum—makes it very difficult to absorb nutrients. In many cases, the ileum (the final portion of the small intestine) can take over some of the roles of the missing segments. But when too much of the intestine is gone, even that adaptation isn't enough. In infants like S.G.V., this can lead to severe malnutrition, dehydration, and growth failure. Symptoms in children Signs of short bowel syndrome in children include: Chronic diarrhea or loose, watery stool Bloating and excessive gas Fatigue Foul-smelling stool Poor weight gain or failure to grow These symptoms come from the body's inability to digest and absorb essential nutrients, fluids, and electrolytes. How is Short Bowel Syndrome treated? Dietary Changes Children with milder forms of SBS may benefit from frequent small meals, high-calorie foods, and supplements of vitamins and minerals. They may need to avoid certain foods that are hard to digest, such as those high in fat, sugar, or fiber. However, in more severe cases—like S.G.V.'s—diet alone is not enough. Total Parenteral Nutrition (TPN) TPN is a method of delivering nutrients directly into the bloodstream through a special IV catheter, bypassing the digestive system entirely. The fluid contains carbohydrates, protein, fats, electrolytes, and vitamins. This is the primary treatment for children with severe SBS. It is often given overnight for 12–16 hours to allow children to be mobile during the day. As in S.G.V.'s case, some children use portable TPN backpacks, which allow them to attend school or go outside while still receiving nutrition. 'If her treatment is interrupted, she will die within days,' said Gina Amato, the family's attorney, to NBC News. However, long-term use of total parenteral nutrition (TPN) can lead to several serious complications. These include bacterial infections, issues with the intravenous catheter, and blood clots. Over time, TPN may also reduce the body's ability to absorb calcium into the bones, increasing the risk of bone weakening. It can contribute to gallbladder disease, kidney damage, and liver problems. In severe cases, these complications may progress to kidney or liver failure. Enteral feeding (Tube Feeding) Some children also need a feeding tube inserted into the stomach or intestines to get liquid nutrition. This may be used in combination with TPN to encourage the intestines to function as much as possible. Complications of Short Bowel Syndrome Because the body can't absorb nutrients the usual way, SBS comes with serious health risks: Malnutrition and vitamin deficiencies Electrolyte imbalance (sodium, potassium, magnesium) Dehydration Gallstones Kidney stones Liver disease from long-term TPN Infections related to central IV lines In infants, complications like cholestasis (bile backup in the liver) and intestinal failure-associated liver disease are particularly dangerous. One step to a healthier you—join Times Health+ Yoga and feel the change
